10X GENOMICS INC's ticker is TXG and the CUSIP is 88025U109. A total of 306 filers reported holding 10X GENOMICS INC in Q4 2020. The put-call ratio across all filers is 0.38 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,663 | -27.6% | 40,317 | -2.0% | 0.01% | -25.0% |
| Q2 2023 | $2,297 | -0.3% | 41,139 | -0.4% | 0.01% | -7.7% |
| Q1 2023 | $2,304 | +58.2% | 41,297 | +3.4% | 0.01% | +44.4% |
| Q4 2022 | $1,456 | -99.9% | 39,947 | +1.3% | 0.01% | +28.6% |
| Q3 2022 | $1,123,000 | -35.5% | 39,437 | +2.5% | 0.01% | -36.4% |
| Q2 2022 | $1,741,000 | -26.5% | 38,467 | +23.5% | 0.01% | -15.4% |
| Q1 2022 | $2,369,000 | -70.2% | 31,144 | -41.7% | 0.01% | -69.0% |
| Q4 2021 | $7,954,000 | +0.9% | 53,399 | -1.4% | 0.04% | -8.7% |
| Q3 2021 | $7,883,000 | -22.3% | 54,149 | +4.6% | 0.05% | -22.0% |
| Q2 2021 | $10,142,000 | +44.6% | 51,790 | +33.7% | 0.06% | +34.1% |
| Q1 2021 | $7,014,000 | +51.4% | 38,750 | +18.4% | 0.04% | +41.9% |
| Q4 2020 | $4,633,000 | +76.4% | 32,720 | +55.3% | 0.03% | +55.0% |
| Q3 2020 | $2,627,000 | +47.3% | 21,070 | +5.5% | 0.02% | +33.3% |
| Q2 2020 | $1,784,000 | – | 19,980 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 1,753,528 | $133,391,000 | 100.00% |
| Foresite Capital Management I, LLC | 750,000 | $57,053,000 | 99.71% |
| 12 West Capital Management LP | 2,518,500 | $191,582,000 | 11.65% |
| Meritech Capital Associates V L.L.C. | 1,336,253 | $101,649,000 | 9.59% |
| Blue Water Life Science Advisors, LP | 211,917 | $16,121,000 | 7.65% |
| Decheng Capital Management III (Cayman), LLC | 303,984 | $23,124,000 | 7.09% |
| FINANCIAL CONSULATE, INC | 154,942 | $11,786,000 | 4.53% |
| Evolutionary Tree Capital Management, LLC | 54,128 | $4,118,000 | 2.86% |
| HARVARD MANAGEMENT CO INC | 186,143 | $14,160,000 | 1.43% |
| Brown Capital Management | 1,663,469 | $126,540,000 | 1.26% |